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OBJECTIVES: Cowden syndrome (CS), associated with germline PTEN mutations, is an autosomal-dominant disorder with
increased frequencies of thyroid and breast cancers. Recent reports document the occurrence of gastrointestinal (GI) polyps
and increased risk of colon cancer in PTEN mutation carriers. Studies to date, however, have not been based on mutation
carriers undergoing active, systematic, routine-interval GI surveillance. Our objective is to document the upper and lower GI
ﬁndings in CS patients undergoing such an active GI surveillance program.
METHODS: In a 5-year period, 3,000 consecutive patients were referred to our high-risk GI cancer clinic for various reasons. Of
these 3,000, 10 met full-blown clinical criteria for the diagnosis of CS. Individuals with identiﬁed PTEN mutations underwent
annual upper and lower endoscopy surveillance programs using dual white light and narrow-band imaging. All biopsies
including archived materials were reviewed by a single dedicated GI pathologist.
RESULTS: Ten PTEN mutation carriers from different ethnic backgrounds were invited and all participated in the active GI
surveillance program. Eight patients had colonic polyps, mostly hyperplastic (eight patients) and hamartomatous (ﬁve patients),
but also adenomatous (three patients), ganglioneuromatous (three patients), and juvenile polyps (two patients). One patient
(10%) had an early-onset rectal cancer (aged 44 years), which was null for PTEN expression on immunohistochemistry.
All patients had gastric polyps and nine (90%) had duodenal polyps, mostly hyperplastic and hamartomatous. Additional three
patients (30%) had adenomatous duodenal polyps.
CONCLUSIONS: PTEN mutation–positive CS patients have a higher frequency of upper GI polyps than previously believed. They
appear prone todevelopadenomatousupper andlower tract dysplasticpolyps andcancer.Thus,the polyps encounteredduring
upper or lower endoscopy in these patients should not be automatically considered innocent hamartomas without malignant
potential. Active surveillance programs in specialized centers should be considered in these patients.
Clinical and Translational Gastroenterology (2011) 2, e5; doi:10.1038/ctg.2011.4; published online 17 November 2011
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INTRODUCTION
Cowden syndrome (CS) is an autosomal-dominant disorder
characterized by multiple hamartomatous and benign and
malignant neoplastic lesions of the skin, mucous membranes,
thyroid, breast, endometrium, and brain.
1–3 Germline muta-
tions in the PTEN tumor suppressor gene are found in 80% of
classic CS.
4,5 CS is very difﬁcult to ascertain, especially in
subtlercases,andrecentlyaclinicalscoringsystembasedona
prospectivestudyof3,042CSandCS-likeindividualshasbeen
proposed.
6 According to this semiquantitative system, a score
o f1 0 ,c a r r y i n ga tl e a s ta3 %l i k e l i h o o do fﬁ n d i n gaPTEN
pathogenic mutation, isminimal for considering PTEN testing.
6
Classically, although CS patients might harbor ‘polyps’
throughout the gastrointestinal tract, they are mostly believed
to be hamartomas without malignant potential. Up to now, the
National Comprehensive Cancer Network (NCCN) guidelines
state that routine gastrointestinal (GI) surveillance in CS
patients is not indicated in the absence of symptoms.
7 Prior to
our recent report,
8 there were scattered reports about the
occurrence of GI polyposis
9–13 but few reports documenting
age-speciﬁc prevalence of gastric and colon cancers in CS
patients.
14–17 In our prospective series of 127 unrelated
individuals with pathogenic PTEN mutations, 69 (54.3%)
underwent at least one endoscopy and most had GI polyps
comprising multiple histologies.
8 Importantly, nine (13%)
mutation carriers in this series had prevalent colorectal
cancers, yielding an age- and sex-adjusted standardized
incidence ratio of 4200. All but one with colorectal carcino-
mas had existing colonic polyposis. What was surprising was
that 16 individuals out of 67 who underwent colonoscopy had
colonic adenomatous polyps and 2 individuals out of 39 who
underwent esophagogastroduodenoscopy (EGD) had upper
GI adenomas. It is important to note, however, that in this
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www.nature.com/ctgseries, upper or lower GI endoscopies were performed as part
of clinical routine, and were not systematically performed on a
regular longitudinal basis. Thus, of the 127 mutation carriers,
67 had one or more colonoscopies, and only 39, an EGD. As
an important caveat to this study, therefore, an important
follow-up study was to document the GI phenotype of PTEN
mutation carriers undergoing systematic GI surveillance
performed by one or very few endoscopists on a regular
longitudinal basis, and having only one or very few patholo-
gists read the histologies.
The High Risk Cancer Clinic (HRCC) at Rabin Medical
Center(RMC) isatertiaryreferral centerof thelargestHMOin
Israel. All CS patients treated at the HRCC participate in a
surveillance program, where they undergo biannual dual
upper and lower endoscopy, using narrow-band imaging
(NBI) at the advanced endoscopy unit from the age of 25
years old, or earlier, if symptomatic. The technique of NBI
allows recognition of ﬂat lesions and helps to recognize
adenomatous changes in both the upper and lower digestive
tract.
18,19 Here, we sought to document the GI endoscopic
and pathologic ﬁndings of 10 PTEN mutation–positive CS
patients who have been systematically surveillanced annually
with dual upper and lower endoscopies at the advanced
endoscopy unit by three endoscopists.
METHODS
Study design. Between January 2005 and December 2009,
we identiﬁed 10 patients with a deﬁnitive diagnosis of CS out
of 3,000 patients referred to the HRCC. Additional three
patients from unrelated families with suspected CS who were
not willing to perform genetic testing were not included in the
analysis. Patients with a genetic diagnosis (PTEN mutation
positive) of CS were offered a surveillance program according
to the NCCN guidelines. Additionally, they were offered an
intensive GI endoscopy surveillance program. Medical records
as well as any endoscopy records and surgical pathology
were reviewed. All pathology slides were reviewed by a single
expert GI pathologist at RMC. Tumor analysis was performed
at the Cleveland Clinic as described below.
Gastrointestinal surveillance program. The program
includes annual upper and lower endoscopy examination
since the age of 25 years old, or earlier, if symptomatic. The
procedures were performed by the advanced endoscopy
team at RMC, using both white light (WL) and NBI for each
segment with the Olympus TM 180 system (high deﬁnition
and NBI) (Japan). Resection of large duodenal polyps was
performed with a duodenoscope Olympus TM 160.
Genetic testing. PTEN mutation analysis was performed in
Eng lab (Genomic Medicine Institute, Cleveland Clinic) or by the
local clinical service lab (MYGAL, Israel). The Eng lab’s PTEN
mutation analysis includes polymerase chain reaction-based
mutation analysis of all nine exons, ﬂanking intronic regions and
promoter as well as large deletion/rearrangement testing per
multiplex ligation-dependent probe ampliﬁcation as described.
6
At MYGAL, Sanger sequencing was applied to all gene exon,
including exon–intron boundaries (at least 20 base pairs).
Tumor analysis. Microsatellite instability testing was
performed using polymerase chain reaction ampliﬁcation of
seven loci (Promega, Madison, WI), including ﬁve mono-
nucleotide repeats (BAT 25, BAT 26, NR-21, NR-24, and
MONO-27) and two pentanucleotide repeats (PentaC and
PentaD) on genomic DNA extracted from formalin-ﬁxed,
parafﬁn-embedded lesional tissue and a paired normal
(germline) sample.
Immunohistochemistry (IHC) for the mismatch repair
proteins, MLH1, MSH2, MSH6, and PMS2, was performed
on standard 5-micron thick deparafﬁnized, formalin-ﬁxed
tissue sections. Monoclonal mouse primary antibodies for all
four proteins (MLH1, MSH2, MSH6 from Biocare Medical,
Concord, CA and PMS2 from BD Pharmingen, San Diego,
CA) were used at 1:10, 1:100, and 1:500 dilutions, respec-
tively, for 90min (MLH1, MSH6, and PMS2) and 30min
(MSH2) incubation times at room temperature.
PTEN IHC was performed with the monoclonal antibody
6H2.1 raised against the terminal 100 amino acids of human
PTEN as previously described, with minor modiﬁcations.
17
Human subjects’ protection. The study has been
approved by the Rabin Medical Center Helsinki committee
and by the Cleveland Clinic Committee for Human Subjects’
Protection, for the respective research activities.
RESULTS
Utilizing the NCCN-2006/International Cowden Consortium
clinical diagnostic criteria, we identiﬁed 10 CS patients out of
3,000 patients referred to the HRCC in the last 5 years. All 10
were found to have germline PTEN mutations. These patients
belong to six different families. Seven patients (70%) were
Jews and the remaining three were Arabs. The current mean
age of the patients with CS is 36.4±14.3 years, and seven
(70%) are males. The research participants’ demographic
characteristics and major phenotypic ﬁndings and PTEN
genotypes are presented in Table 1.
Colorectal polyps and carcinoma. At least one colono-
scopy was performed for all 10 patients; each segment was
examined by both WL and NBI (Table 2). The average age at
ﬁrst colonoscopy was 31.7 years (range 9–59 years) and
the mean number of colonoscopies per patient was 2.4
(range 1–5). Five patients (50%) underwent colonoscopy
because they were symptomatic (rectal bleeding: 3, iron-
deﬁciency anemia: 2). Four patients (40%) had the ﬁrst
procedure because of the diagnosis of CS and one under-
went the procedure after upper GI polyps were detected. In
Table 2 we specify for each lesion whether it was screen
detected or symptom detected.
Colorectal polyps were identiﬁed in 8 of 10 (80%) research
participants. The lower GI polyps were found throughout the
colon with increased density of polyps in the rectum. Eight
subjects (80%) had hyperplastic polyps, ﬁve (50%) had
hamartomatous polyps, three (30.0%) had ganglioneuroma-
tous polyps, three had adenomatous polyps (one of them at
age 29 years), and two (20.0%) had juvenile polyps.
It should be noted, however, that pathology results from
cold biopsies are often misleading. In ﬁve cases, we used the
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Clinical and Translational Gastroenterologytechnique of cold biopsy before snare polypectomy. In three
out of those ﬁve patients, the superﬁcial biopsy contained
‘‘hyperplastic tissue’’, while inspection of the whole resected
polyp revealed that it contained hamartomatous components.
All the adenomatous lesions were detected during the
surveillance program (Table 2). Using both WL and NBI, we
were able to identify correctly adenomatous polyps in three
patients and to resect these lesions. It is impossible to decide
whether it is the careful dual inspection or the added value of
NBI that lead to the detection of adenomas.
One out of the ten PTEN mutation–positive patients (10%)
had rectal cancer at an early age (44 years). He was found to
have synchronous hyperplastic, hamartomatous, and adeno-
matous polyps. The cancer was found to be microsatellite
stable (MSS), and IHC showed normal nuclear expression of
MLH1, MSH2, MSH6, and PMS2 in the carcinoma cells and
PTEN expression was null by IHC.
Upper GI ﬁndings. All patients (100%) underwent at least one
EGD (Table 3). The average age at ﬁrst EGD was 35.6 years
(range 21–61 years) and the mean number of endoscopies per
patient was 2.7 (range 1–4). Three patients (30%) were
symptomatic (iron-deﬁciency anemia: 2, hematemesis: 1), and
in seven patients (70%) the ﬁrst procedure was performed while
asymptomatic as part of the surveillance program.
Table1 Patients’ characteristics andfeaturesobservedinourPTEN mutation–
positive patients
All 10 (100%)
Age (mean, s.d.) 40.8±16.0 (years)
Gender
Male 7 (70%)
Female 3 (30%)
Origin
Jew 7 (70%)
Arab 3 (30%)
Head
Macrocephaly 3 (30%)
Lhermitte-Duclos 1 (10%)
Skin
Trichilemmomas 4 (40%)
Penile freckling 2 (28.5%
a)
Breast
Cancer 1 (33.3%
b)
Thyroid
Cancer 4 (40.0%)
Goiter 3 (33.3%)
Genitourinary
Endometrial ﬁbroid 1 (33.3%
b)
Mixed germ cell tumor 1 (33.3%
b)
Upper GI
Glycogenic acanthosis 8 (80%)
Gastric hyperplastic 10 (100%)
Gastric hamartomatous polyps 4 (40%)
Duodenal hyperplastic 9 (90%)
Duodenal hamartomatous polyps 1 (10%)
Duodenal adenomatous polyps 3 (30%)
Colon and rectum
Hyperplastic 8 (80%)
Hamartomatous polyps 5 (50%)
Juvenile polyps 2 (20%)
Ganglioneuromatous polyps 3 (30%)
Adenomatous polyps 3 (30%)
Cancer (early age) 1 (10%)
aPercent of males.
bPercent of females. Mutation: 350insA (n¼2), 302delT
(n¼3), R335X (n¼1), Q244X (n¼1), ivs6/A-G (n¼2), in one case speciﬁc
location of the mutation was not reported.
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Clinical and Translational GastroenterologyAll 10 individuals had abnormal upper GI endoscopic
ﬁndings, which varied from severe esophageal acanthosis
andmassivegastroduodenalpolyposistoonlyafewdiminutive
gastricpolyps.Eightpatients(80%)hadglycogenicacanthosis,
of which ﬁve had severe acanthosis, and in two cases, the
presentation was mild. Gastric polyps were detected in all
patients (100%), mostly hyperplastic with varying sizes and
number. Duodenal polyps were observed in nine patients
(90%; Figure 1). Using both WL and NBI, we were able to
identify correctly adenomatous polyps in three patients and to
resect these lesions (Figure 2). Again,itisimpossibletodecide
whether it is the careful dual inspection or the added value of
NBI use that lead to the detection of adenomas.
In one patient, a carpeting of polyps in the duodenal bulb
proved to contain hyperplastic Brunner glands, and in one
case, a 15mm polyp in the second duodenal part contained
Brunner gland hyperplasia and gastric metaplasia.
Other clinical features. Clinical features characteristic of or
suspicious of CS also were recorded for all subjects
(Table 1). Four patients (40%) had thyroid cancer: follicular
variant of papillary thyroid carcinoma in a female at aged 13
years and in her father at age 61 years, and two epithelial
thyroid carcinomas (of unknown histology) in an adult male
aged 40 years and female at age 48. Of the three female
patients, one had breast cancer at age 48 years, the second
had mixed germcell tumor at age 7 years and the third had
endometrial ﬁbroid. Macrocephaly was evident in the three
patients (30%) and Lhermitte-Duclos in one.
DISCUSSION
While the increased risk for breast and thyroid cancer is well
documented, CS is not considered as a syndrome with an
increased colon cancer or upper GI cancer risk, at least in the
most studied population, whites of European ancestry. In fact,
Online Mendelian Inheritance in Man (OMIM)
20 does not
report colon or upper GI cancer in CS patients, and currently,
the NCCN states that CRC screening in CS patients is not
indicated in the absence of symptoms, but rather focuses
largely on the increased risks of breast, thyroid, and
endometrial cancers.
7 A currently updated Gene Reviews
21
recommend baseline colonoscopy at age 50 years, unless
symptoms arise earlier, and if only hamartomatous polyps are
found, the American Cancer Society guidelines for colon
cancer screening (i.e., annual fecal occult blood testing and
sigmoidoscopy every 5 years or colonoscopy every 10 years)
should be followed.
21
In late 2010 and this year, we analyzed prospective series
of individuals who met classic criteria for the clinical diagnosis
of CS (NCCN-2006)
7 and relaxed criteria (full criteria minus
one)alsoreferredtoasCS-like.
6,8Fortheﬁrsttime,upperand
lower GI polyps, comprising broad histologies, and even
polyposis are an important part of the phenotypic spectrum of
individuals with pathogenic germline PTEN mutations (var-
iants of unknown signiﬁcance were excluded from analysis)
8
and a clinical feature signaling the potential of the diagnosis.
6
However, the caveat to these analyses is that examination of
the upper and/or lower GI tracts was performed as part
of clinical care, and not systematically and periodically
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Clinical and Translational Gastroenterologyperformed as a routine. The current study directly addresses
this caveat because all PTEN mutation–positive individuals
hereweregivenactiveannualupperandlowerGIsurveillance
from the age of 25 years, and starting earlier should there
be symptoms. Conﬁrming our previous observation, this
current study reveals 8 (80%) with colonic polyps of varying
histologies and one male, currently, 61, with rectal carcinoma
diagnosed at age 44. As with the Heald et al.
8 observations,
this cancer was accompanied by prevalent colonic polyposis.
Indeed, our patient who was diagnosed with rectal cancer
had undergone several endoscopies in the ‘‘community’’
where some of the polyps were biopsied, and were found
to be ‘‘inﬂammatory’’ or hyperplastic, while careful colono-
scopy using dual WL and NBI inspection we detected large
adenomatous polyps (up to 15mm) that were removed again
with the endoscope. Thus, polyposis may be an indicator
of future colorectal cancer risk in individuals with PTEN
mutations.
The rectal cancer identiﬁed here was MSS and showed
normal expression of MLH1, MSH2, MSH6, and PMS2
proteins but was PTEN protein null by IHC. The fact that this
MSS rectal tumor was completely null for PTEN protein
expression strongly suggests that this rectal cancer was
facilitated by the existing germline PTEN mutation.
22
Up to our recent GI series by Heald et al.,
8 there were
several reports of gastric cancers in PTEN mutation
carriers,
14,15 but no reports about adenomatous polyps in
the upper GI tract. In our current study from active GI
surveillance, we report that all patients had upper GI polyps
and that three patients (30%) had adenomatous polyps, the
latter contrasts with only 2 of 39 (5%) research participants
found to have upper GI adenomatous polyps when EGD was
performed for clinical reasons
8 (P¼0.05). It should be noted
that the mean age of both series are similar (40 and 39 years).
Two plausible explanations for the higher prevalence of GI
adenomas include the use of NBI, which was used to
advantage to detect all three with upper GI adenomatous
polyps in this series, and the active yearly surveillance of both
the upper and lower GI tracts. Therefore, as individuals with
PTEN mutations may routinely develop numerous upper GI
polyps and it is impossible to resect every visualized polyp, it
seems reasonable to examine the polyps with dual WL and
NBI and endoscopically resect only the large polyps and/or
those that seem to be adenomatous.
Finally, although the Heald et al.
8 series could not reveal a
genotype–GI phenotype correlation, we note here that all 10
individuals in this present have truncating mutations. We
caution, however, that the current sample size is relatively
small and we are unaware of the general genotypic spectrum in
the population served by RMC. Nonetheless, we believe that
our two series (Heald et al.;
8 this study) begin to support routine
GI surveillance on asymptomatic CS patients, conﬁrming the
suggestion that surveillance colonoscopies begin before 35
years of age. Because of the prominence of the upper GI
phenotype, especially adenomas, upper GI surveillance has an
important role as well. However, we do not know at what age to
begin and how frequently. Because the PTEN-related GI
phenotype includes multiple polyps, it may be conservative to
utilize such technological advances as NBI endoscopy to
differentiate adenomas. The place of NBI endoscopy and other
modern strategies should be further characterized.
From our initial experience with our PTEN mutation–
positive CS patients, GI features including adenomas and
cancer may be more prevalent than originally thought.
However, our study included only 10 patients and only in
about half of the cases the ﬁndings were detected by the
screening program among asymptomatic patients. Therefore,
we strongly urge that another independent large series be
prospectively accrued for systematic study of prospective
routine surveillance of the GI tract in PTEN mutation–positive
CS. It is also important to emphasize that various compo-
nent features arising from identical mutations may result
in vastly different phenotypes in individuals of different
ancestral backgrounds, and so the international community
should come together to perform comparative phenotype
Figure 1 Duodenal view in Cowden syndrome patient using white light.
Figure 2 Duodenal view in Cowden syndrome patient using narrow-band imaging.
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Clinical and Translational Gastroenterologystudies. Finally, we suspect that lifelong mechanical removal
of polyps annually might become unfeasible to patients and
to our sagging health-care systems, and call upon a global
collaborative trial of novel targeted therapeutic approaches as
the use of mammalian target of rapamycin inhibitors (clinical
trial NCT00971789).
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WHAT IS CURRENT KNOWLEDGE
| Cowden syndrome (CS) patients caused by germline
PTEN mutations are prone to thyroid and breast cancer.
| There are reports about hyperplastic and hamartoma-
tous polyps in these patients.
| Recent report has suggested that the prevalence of
adenomas and colorectal cancer may be higher than
previously thought.
WHAT IS NEW HERE
| A signiﬁcant proportion of patients was found to harbor
duodenal and colonic adenomatous polyps. Therefore,
the polyps encountered during upper or lower endo-
scopy in these patients should not be considered
automatically as innocent hamartomas.
| Surveillance programs in specialized centers should
be considered in these patients.
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